Skip to main content
S&P 5007,650.50+0.17%DOW51,682.64-0.18%NASDAQ26,522.54+0.39%BTC$81,273.00+6.27%ETH$2,618.91+7.14%GOLD$4,415.90+0.37%OIL$95.47-1.81%
Smart Investors Daily
TE

NYSE · TEVA

Teva Pharmaceutical Industries Limited

Healthcare · Drug Manufacturers - Specialty & Generic

$38.98

Down-$0.21 (-0.54%)

Updated Sep 20, 2026, 3:34 PM

SID Score

6.7/10

Composite research score

Smart Money

56/100

Neutral

Market cap
34.61B
P/E ratio
-217.43
Dividend yield
0.00%
52-week range
$18.21 – $39.70
Volume
5.48M
Avg. volume
11.34M

Price performance

TEVA price history

1M range · 19 trading sessions · Daily adjusted prices

TEVA closed at $38.98 after 19 trading sessions, up 5.55% for the selected period.

Last close
$38.98
Period change
+5.55%
Period low
$36.05
Period high
$39.25
Daily close
View OHLC price history
TEVA OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 18, 2026$38.90$39.38$38.66$38.985.48M
Sep 17, 2026$38.96$39.70$38.71$39.195.52M
Sep 16, 2026$39.02$39.52$38.32$38.534.82M
Sep 15, 2026$38.71$39.49$38.11$39.257.13M
Sep 14, 2026$37.66$39.22$37.00$38.724.38M
Sep 11, 2026$36.46$37.11$36.06$37.092.86M
Sep 10, 2026$36.37$36.75$36.04$36.354.01M
Sep 9, 2026$36.82$37.315$36.47$36.854M
Sep 8, 2026$35.89$36.965$35.42$36.764.62M
Sep 4, 2026$36.40$36.93$36.13$36.367.4M
Sep 3, 2026$37.98$38.06$36.33$36.623.9M
Sep 2, 2026$36.65$37.59$35.742$37.497.69M
Sep 1, 2026$36.52$36.55$35.85$36.193.52M
Aug 31, 2026$36.17$36.3347$35.62$36.055.78M
Aug 28, 2026$37.37$37.42$36.37$36.443.14M
Aug 27, 2026$37.72$38.37$37.535$37.624.72M
Aug 26, 2026$37.70$38.055$37.07$37.924.82M
Aug 25, 2026$37.13$38.11$37.09$38.105.28M
Aug 24, 2026$37.30$37.32$36.75$36.933.34M

Latest TEVA news

The latest Smart Investors Daily articles mentioning TEVA.

Stock researchCompany · Overview

TEVA research

Overview

Company profile and research snapshot.

Company profile

Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$32.67
Implied upside
—
Analysts
—
TEVA recent ratings
DateFirmRatingTarget
Nov 25, 2020OppenheimerPerform—
Nov 6, 2020BMO CapitalMarket Perform—
Aug 6, 2020SVB LeerinkMarket Perform—
Aug 6, 2020BarclaysEqual-Weight—
Jul 27, 2020Goldman SachsNeutral—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 18, 2026

New Teva Study Identifies the Attributes that Healthcare Providers Prioritize when Selecting a Treatment for Tardive Dyskinesia in Older Patients

New data revealed that healthcare providers prioritize drowsiness risk, duration of available data demonstrating long-term response and drug-drug interaction profile when selecting a treatment for tardive dyskinesia (TD) in patients aged ≥55 yearsAcross all four patient profiles, AUSTEDO® (deutetrabenazine) was most closely related to the attributes most valued by healthcare providersThese findings from Teva detail specific healthcare provider preferences around tolerability and efficacy, while

Yahoo · Sep 18, 2026

Teva Highlights New Real-World Data Showing UZEDY® (risperidone) Outperforms Other Long-Acting Injectables in Keeping Schizophrenia Patients on Treatment, While Reducing Emergency Care and Healthcare Costs

New findings show favorable treatment continuity for UZEDY compared to other long-acting injectables in schizophrenia, as well as oral antipsychotics in bipolar I disorder (BD-I)The new real-world data also show that UZEDY decreased emergency room visits and hospitalizations, lowering overall healthcare resource utilization and delivering over $1,000 per patient per month in direct cost savingsThe breadth of clinical evidence presented highlights Teva’s ongoing commitment to evaluating how thera

Yahoo · Sep 18, 2026

Teva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophrenia in Adults

In a post hoc analysis of the open-label safety stage of the Phase 3 SOLARIS trial, more than half of participants receiving TEV-'749 achieved stabilization, few relapsed and more than one-fifth of participants receiving TEV-'749 for ≥ 6 months met criteria for remission Treatment switch analyses provide clinical insights into maintaining established therapeutic ranges of olanzapine when initiating TEV-'749 from existing regimens Ahead of the Q4 FDA anticipated approval decision, the growing bod

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By